These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 18791717

  • 1. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
    Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ.
    Cancer Chemother Pharmacol; 2009 May; 63(6):1035-48. PubMed ID: 18791717
    [Abstract] [Full Text] [Related]

  • 2. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
    Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ.
    Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
    Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, Rubin EH, Tan AR.
    Clin Cancer Res; 2008 Sep 15; 14(18):5856-63. PubMed ID: 18794097
    [Abstract] [Full Text] [Related]

  • 4. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
    Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, Mross K.
    Clin Cancer Res; 2005 Jul 01; 11(13):4843-50. PubMed ID: 16000582
    [Abstract] [Full Text] [Related]

  • 5. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.
    Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R.
    Clin Pharmacol Ther; 1998 Jan 01; 63(1):11-25. PubMed ID: 9465838
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Indirect-response model for the time course of leukopenia with anticancer drugs.
    Minami H, Sasaki Y, Saijo N, Ohtsu T, Fujii H, Igarashi T, Itoh K.
    Clin Pharmacol Ther; 1998 Nov 01; 64(5):511-21. PubMed ID: 9834043
    [Abstract] [Full Text] [Related]

  • 8. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
    Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N.
    Clin Cancer Res; 2005 Jun 01; 11(11):4136-43. PubMed ID: 15930349
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ, Mathôt RA, van Tellingen O, Schellens JH, Beijnen JH.
    Cancer Chemother Pharmacol; 2002 Jul 01; 50(1):16-24. PubMed ID: 12111107
    [Abstract] [Full Text] [Related]

  • 11. Measurement of fraction unbound paclitaxel in human plasma.
    Brouwer E, Verweij J, De Bruijn P, Loos WJ, Pillay M, Buijs D, Sparreboom A.
    Drug Metab Dispos; 2000 Oct 01; 28(10):1141-5. PubMed ID: 10997930
    [Abstract] [Full Text] [Related]

  • 12. Mechanism-based models for topotecan-induced neutropenia.
    Léger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, Sparreboom A, Chatelut E.
    Clin Pharmacol Ther; 2004 Dec 01; 76(6):567-78. PubMed ID: 15592328
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM, Schellens JH, Van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, Koopman FJ, Schot ME, Ten Bokkel Huinink WW, Beijnen JH.
    Br J Cancer; 2001 Nov 16; 85(10):1472-7. PubMed ID: 11720431
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A.
    Clin Cancer Res; 2002 Apr 16; 8(4):1237-41. PubMed ID: 11948138
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
    Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH.
    Cancer Res; 1996 May 01; 56(9):2112-5. PubMed ID: 8616858
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
    Tsushima T, Kasai H, Tanigawara Y.
    Cancer Chemother Pharmacol; 2020 Oct 01; 86(4):487-495. PubMed ID: 32930844
    [Abstract] [Full Text] [Related]

  • 20. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
    Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2007 Jan 01; 59(1):43-50. PubMed ID: 16680462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.